Pharmaceutical

Doctor who pushed testosterone replacement therapy ordered to turn over payment records from drug companies

Low T1 Doctor who pushed testosterone replacement therapy ordered to turn over payment records from drug companies A doctor considered a “key opinion leader” in the promotion of testosterone replacement therapy to doctors and medical schools must turn over records of payment he received from some 18 pharmaceutical companies involved in multidistrict litigation (MDL) accusing the drug companies of withholding testosterone risks, an Illinois federal judge ruled.

Dr. Abraham Morgantaler was ordered by U.S. District Judge Matthew Kennelly to turn over tax forms and other documents showing payments he received from the companies. Morgantaler has been fighting the subpoena served to him by the plaintiffs steering committee, arguing that his disorganization made it difficult for him to collect all the documents plaintiffs seek.

Judge Kennelly said a person should not be allowed to hide behind his disorganization when they are asked to turn over documents as part of a court case.

Morgantaler was also ordered to hand over PowerPoint presentations made to doctors and medical schools promoting testosterone treatments to counter low libido and weight gain in aging men.

Manufacturers of testosterone replacement products face about 6,000 lawsuits consolidated in a multidistrict litigation in the Northern District of Illinois, alleging the companies used aggressive marketing to lure men into asking their doctors for the treatment while withholding information that use of the product could cause potentially fatal heart attacks, strokes, and blood clots.

The first bellwether trials are scheduled for 2017.

Source: Law360